ACST - Acasti Pharma GAAP EPS of -$0.95 misses by $0.53
2023-06-23 16:05:53 ET
- Acasti Pharma press release ( NASDAQ: ACST ): FY GAAP EPS of -$0.95 misses by $0.53 .
- Cash, cash equivalents and short-term investments totaled $27.9 million as of March 31, 2023, compared to $43.7 million in cash, cash equivalents and short-term investments as of March 31, 2022.
- Based on management's current projections, current cash, cash equivalents and short-term investments are expected to be sufficient to fund the Company through calendar Q2 2025, facilitating achievement of critical value inflection milestones, including a potential New Drug Application filing for GTX-104.
For further details see:
Acasti Pharma GAAP EPS of -$0.95 misses by $0.53